Experimental cell shot aims to tame Out-of-Control nerve attacks
Disease control
Recruiting now
This early-phase study tests a new cell therapy called CNCT19 in 18 adults with severe autoimmune nerve diseases that have not responded to standard treatments. The therapy targets and removes certain immune cells (CD19+ B cells) that are attacking the nervous system. The main go…
Phase: EARLY_PHASE1 • Sponsor: Juventas Cell Therapy Ltd. • Aim: Disease control
Last updated May 15, 2026 11:54 UTC